Interferon-γ and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment

Circulation

Volumn 101, Issue 15, 2000, Pages 1785-1791

  Nakagomi, Akihiro ^a   Freedman, S Ben ^a   Geczy, Carolyn L ^a  

^a NONE

Author keywords

Atherosclerosis; Coagulation; Coronary disease; Immune system; Inflammation

Indexed keywords

BIOLOGICAL FACTOR; GAMMA INTERFERON; LIPOPOLYSACCHARIDE;

ADULT; AGE; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CORONARY ARTERY DISEASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; INFLAMMATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOSIS;

EID: 0034681947     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.15.1785     Document Type: Article

References (46)

1. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141-212. Review.
2. Kunshner I, Broder ML, Karp D. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest. 1978;61:235-242.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-1016.
4. Koening W, Froehlich M, Sund M, Doering A, Fischer H, Loewel H, Hutchinson W, Pepys M. C-reactive protein (CRP) predicts risk of coronary heart disease (CHD) in healthy middle-aged men: results from the MONICA-Augsburg cohort study. Circulation. 1997;96(suppl I):I-99. Abstract.
5. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17:1121-1127.
6. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996; 144:537-547.
7. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol And Recurrent Events (CARE) Investigators. Circulation. 1998;98:839-844.
8. Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation. 1998;97:2000-2002.
9. Haverkate F, Thompson SG, Pyke SDM, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-466.
10. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, Rebuzzi AG, Ciliberto G, Maseri A. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.
11. Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med. 1987;111:265-269.
12. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4: 361-368.
13. Pue CA, Mortensen RF, Marsh CB, Pope HA, Wewers MD. Acute phase levels of C-reactive protein enhance IL-1β and IL-1ra production by human blood monocytes but inhibit IL-1β and IL-1ra production by alveolar macrophages. J Immunol. 1996;156:1594-1600.
14. Whisler RL, Proctor VK, Downs EC, Mortensen RF. Modulation of human monocyte chemotaxis and procoagulant activity by human C-reactive protein (CRP). Lymphokine Res. 1986;5:223-228.
15. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.
16. Tracy R. Atherosclerosis, thrombosis and inflammation: a question of linkage. Fibrinolysis Proteolysis. 1997;11(suppl 1):137-142.
17. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors Vila and X. Lab Invest. 1996; 75:451-461.
18. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86:2839-2843.
19. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation. 1996; 94:1226-1232.
20. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina: implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation. 1996;94:3090-3097.
21. Libby P, Hansson K. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-14.
22. Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis: CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol. 1996;149:359-366.
23. Carlsen E, Mette B, Stinessen MB, Prydz H. Differential effect of α Interferon and γ interferon on thromboplastin response in monocytes and endothelial cells. Clin Exp Immunol. 1987;70:471-478.
24. Moon DK, Geczy CL. Recombinant IFN-γ synergizes with lipopolysac-charide to induce macrophage membrane procoagulants. J Immunol. 1988;141:1536-1542.
25. Walsh JD, Geczy CL. Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide. Thromb Haemost. 1991;66:552-558.
26. Davis SR. The therapeutic use of androgens in women. J Steroid Biochem Mol Biol. 1999;69:177-184.
27. Sarrel PM. Psychosexual effects of menopause: role of androgens. Am J Obstet Gynecol. 1999;180:319-324.
28. Osterud B. A global view on the role of monocytes and platelets in atherogenesis. Thromb Res. 1997;81:1-22.
29. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet. 1997;349:769-771.
30. Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, Takazoe K, Kugiyama K, Tsuji I, Kumeda K, Nakamura S. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol. 1998;81:22-26.
31. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gesini GF, Seneri GGN. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost. 1998;79:495-499.
32. Annex BH, Denning SM, Channon KM, Sketch MH Jr, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91:619-622.
33. Kaikita K, Ogawa H, Yasue H, Takeya M, Takahashi K, Saito T, Hayasaki K, Horiuchi K, Takizawa A, Kamikubo Y, Nakamura S. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol. 1997;17:2232-2237.
34. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
35. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid, a protein in severe unstable angina. N Engl J Med. 1994;331: 417-424.
36. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease: FRISC Study Group: Fragmin during Instability in Coronary Artery Disease. Circulation. 1997;96:4204-4210.
37. Neri Semen GG, Prisco D, Martini F, Gori AM, Brunelli T, Poggesi L, Rostagno C, Gensini GF, Abbate R. Acute T-cell activation is detectable in unstable angina. Circulation. 1997;95:1806-1812.
38. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394:200-203.
39. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
40. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
41. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-613.
42. Peterson LR. Estrogen replacement therapy and coronary artery disease. Curr Opin Cardiol. 1998;13:223-231.
43. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary atherosclerosis by 17-β estradiol in ovariectomized monkeys. Arteriosclerosis. 1990;10:1051-1057.
44. Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest. 1991;87:1274-1279.
45. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO III. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med. 1997;336:683-690.
46. Aune B, Oian P, Omsjo I, Osterud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood: a beneficial effect on atherogenesis and thrombus formation? Am J Obstet Gynecol. 1995;173:1816-1820.